Synaptogenix Inc
SNPX
Get informed when a big investor buys or sells
+ FollowMarket Cap$58.73M
Close$
$14.31
82.3% upside
Current Fair Value
82.3% upsideUndervalued by 82.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $58.73 Million |
|---|---|
| Enterprise Value | $56.36 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $-8.81 |
| Beta | - |
| Outstanding Shares | 7,481,700 |
Return
| Return on Equity | -168062.02% |
|---|---|
| Return on Assets | -137723.51% |
| Return on Invested Capital | -45070.90% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 3.93 |
| Enterprise Value to Revenue | 665.72 |
| Enterprise Value to EBIT | -0.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 14, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Synaptogenix Inc
5 employees
CEO: Joshua N. Silverman TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neuro...